{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interleukin&page=2",
    "query": {
      "condition": "Interleukin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interleukin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:12:23.270Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06908577",
      "title": "An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Tozorakimab",
          "type": "DRUG"
        },
        {
          "name": "Autoinjector (AI) Device",
          "type": "DEVICE"
        },
        {
          "name": "Accessorised Prefilled Syringe (APFS) Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 254,
      "start_date": "2025-04-07",
      "completion_date": "2025-11-25",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06908577"
    },
    {
      "nct_id": "NCT05334368",
      "title": "Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypereosinophilic Syndrome"
      ],
      "interventions": [
        {
          "name": "Depemokimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2022-09-06",
      "completion_date": "2028-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Southfield",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05334368"
    },
    {
      "nct_id": "NCT02200445",
      "title": "Low Dose IL-2 for Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Interleukin-2 (aldesleukin).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scott B. Snapper, MD PHD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 26,
      "start_date": "2015-02",
      "completion_date": "2021-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02200445"
    },
    {
      "nct_id": "NCT06052618",
      "title": "Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "KSHV Inflammatory Cytokine Syndrome (KICS)",
        "Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 75,
      "start_date": "2025-03-17",
      "completion_date": "2034-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06052618"
    },
    {
      "nct_id": "NCT00307437",
      "title": "A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab (CNTO 1275) 45 mg",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab (CNTO 1275) 90 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor Research & Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1230,
      "start_date": "2005-05",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00307437"
    },
    {
      "nct_id": "NCT00553618",
      "title": "Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Proleukin and Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2007-08",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00553618"
    },
    {
      "nct_id": "NCT04856930",
      "title": "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Imsidolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 149,
      "start_date": "2021-07-07",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Northridge, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04856930"
    },
    {
      "nct_id": "NCT04856917",
      "title": "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Imsidolimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 123,
      "start_date": "2021-05-15",
      "completion_date": "2022-03-29",
      "has_results": true,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 14,
      "location_summary": "Hot Springs, Arkansas • Fountain Valley, California • Sherman Oaks, California + 9 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Sweetwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04856917"
    },
    {
      "nct_id": "NCT05309616",
      "title": "Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Subglottic Stenosis"
      ],
      "interventions": [
        {
          "name": "Taltz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-02-20",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05309616"
    },
    {
      "nct_id": "NCT04494724",
      "title": "Clazakizumab vs. Placebo - COVID-19 Infection",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Infection"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2020-07-13",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-31",
      "last_synced_at": "2026-05-22T08:12:23.270Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04494724"
    }
  ]
}